Φορτώνει......
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group
BACKGROUND: Failure-free survival (FFS) and overall survival (OS) rates improved on Intergroup Rhabdomyosarcoma Study (IRS)-IV compared with IRS-III for patients with subset 2 (stage 1, group III non-orbit or stage 3, group I/II) low-risk embryonal rhabdomyosarcoma (ERMS) with the addition of cyclop...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cancer |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5662934/ https://ncbi.nlm.nih.gov/pubmed/28211936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30613 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|